Pharvaris’ Post

Inimmune, a biotech company within the Two Bear Capital portfolio, announced the publication of pre-clinical efficacy and safety data for INI-2004. “Intranasal administration of a synthetic TLR4 agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization” was published in Frontiers in Immunology on July 23, 2024. Access the full report here: https://lnkd.in/etGpSTiM This research highlights the significant disease modifying impacts of INI-2004 in allergic disease following intranasal administration and describes the remarkable safety profile of this innovative treatment. Read the press release below. Keep up to the great work Jay Evans, David Burkhart, Helene Bazin-Lee. https://lnkd.in/ez7B_TC7 #TwoBearCapital #InImmune #Biotech

Exciting new findings on #Briquilimab research were shared at the recent AAAAI Annual Meeting, shedding light on advancements in allergy and asthma insights. Stay informed on the latest developments in immunology and research trends. #AllergyInsights #ResearchUpdates'

Tomorrow, #TeamIgGenix heads to the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, to present groundbreaking research on its SEQ SIFTER™ antibody discovery platform supporting continued advancement of IGNX001, an IgG4 monoclonal antibody-based therapeutic candidate for #peanutallergy. IgGenix will also be presenting data on how IgGenix's novel antibodies can be used as effective reagents in #allergen quantification and testing. Learn more: https://bit.ly/3SOJ543 #AAAAI24

In early June 2024, our portfolio company, Allergy Therapeutics, provided further detail from positive top line results from G306 Phase III field trial to evaluate efficacy and safety of Grass MATA MPL. The trial successfully met its primary endpoint. The full results, including secondary and exploratory endpoints were presented in the European Academy of Allergy and Clinical Immunology - EAACI in June 2024. The company is now progressing towards a swift submission for the Marketing Authorisation Application for its #Grass MATA MPL immunotherapy. Positive discussions with the Paul Ehrlich Institut and the inclusion of US patients in future studies support their strategy for a Biologics License Application in the United States. CEO Manuel Llobet is optimistic about the transformative potential of the #vaccine for allergy sufferers worldwide. For more information on the research read the full press release here: https://lnkd.in/dRwv6D2y If you have any questions on this or any of our other Portfolio companies, please do not hesitate to contact us. #EAACI Conference 2024 #G306 Phase III field trial #2024Q4 #GrassAllergy #AllergyTherapeutics #Vaccine #License

Our review article was published in Current Opinion in Allergy and Clinical Immunology. The highlights of the review are as follow: ~Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) are severe cutaneous adverse drug reactions characterized by widespread epithelial detachment and blistering, which affects the skin and mucocutaneous membranes. ~ No targeted therapies for SJS/TEN currently exist and so the mainstay of management remains supportive care. ~Though our understanding of the pathogenesis of SJS/TEN has advanced from both an immunological and dermatological perspective, this knowledge is yet to translate into the development of new targeted therapies. The key points are: ~ A greater understanding of SJS/TEN pathogenesis will unlock novel therapeutic options and predisposing risk factors. ~ Advanced skin culture models will facilitate understanding and provide screening tools for assessing SJS/TEN therapeutics. ~ Significant inter-individual variability exists in SJS/TEN. Serum/blister-fluid profiling offers a route to personalized medicine. You can read the full article by clicking on the link below. Dan Carr Dr Kehinde Ross Rebecca Jensen

Positive Results from Pivotal Study for Bryn Pharma's Investigational Epinephrine Nasal Spray Published in the Journal of Allergy and Clinical Immunology: Global The results showed that NDS1C provides comparable rates of absorption, with overall higher and more sustained epinephrine plasma concentrations, compared to two intramuscular (IM) treatments (0.3 mg epinephrine autoinjector and 0.5 mg manual syringe). “The publication of our pivotal NDS1C data in JACI Global further validates our ambition to develop an epinephrine product that is comparable to the outpatient standard of care, the EpiPen® autoinjector. We are pleased that the published results from our clinical development program are able to provide that peace of mind to the anaphylaxis community, in addition to supporting the potential of a needle-free, small, easy-to-use and affordable option,” said Sandy Loreaux, chief executive officer at Bryn Pharma. “We are confident that, if approved, NDS1C will offer a novel, practical and convenient alternative to needle-based administration routes to help overcome some of the persisting barriers that cause patients and caregivers experiencing an anaphylactic attack to delay or avoid treatment.” Read Bryn Pharma's full press release: https://buff.ly/3RmEjda #FAACT #FoodAllergy #FoodAllergies #Anaphylaxis #Epinephrine #Intranasal #NasalSpray #AllergyAwareness #FoodAllergyAwareness #FoodAllergyLife #FoodAllergyFamily #LearnTheFAACTs #KnowTheFAACTs #ShareTheFAACTs

ALLERGEN IMMUNOTHERAPY For individuals with allergies, allergen immunotherapy (AIT) stands out as the sole disease-modifying therapy presently available, offering enduring benefits in alleviating patient symptoms and enhancing overall quality of life. I'm excited to share that we have recently published a review article on fish allergen immunotherapy - diving deep and exploring the current practices and providing practical recommendations for future development in this area. Key areas of discussion in our paper include: *The validity of sustained unresponsiveness as an endpoint for fish immunotherapy; *The pivotal role of precision diagnostics and patient education in gauging the success of allergen immunotherapy; and *Strategies for enhancing allergen immunotherapy formulations by integrating therapeutic modalities, such as biologics and AIT. I extend my gratitude to my esteemed co-authors, Prof Amir Hamzah Abdul Latiff, Kashaf Nadeem and Ervin Yap for their invaluable contributions to this manuscript. The paper is freely accessible for your reading pleasure at https://lnkd.in/dbnf5avF. #allergy #immunotherapy #fish

𝐏𝐡𝐚𝐫𝐯𝐚𝐫𝐢𝐬 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐬 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐬 𝐢𝐧 𝐇𝐀𝐄 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐚𝐭 𝐀𝐀𝐀𝐀𝐈 𝟐𝟎𝟐𝟒 Pharvaris Pharvaris, a clinical-stage company focused on novel oral bradykinin B2 receptor antagonists for hereditary angioedema (HAE) attacks, will present two posters at the American Academy of Allergy, Asthma, & Immunology (AAAAI) 2024 Annual Scientific Meeting in Washington D.C. from February 23-26, 2024. Poster 1: "Efficacy and Safety of Oral Deucrictibant in Prophylaxis of HAE Attacks: CHAPTER-1 Phase 2 Trial" presents promising results on deucrictibant's efficacy in reducing HAE attack rates by 79.3% to 84.5% compared to placebo, with a favorable safety profile. Poster 2: "Understanding Reasons for Untreated HAE Attacks & Patient Satisfaction with On-Demand Treatment" discusses insights from a real-world study on barriers to HAE treatment decision-making. Dr. Peng Lu Peng Lu, Pharvaris's Chief Medical Officer, highlights deucrictibant's potential as the first oral therapy offering injectable-like efficacy and a favorable safety profile for HAE prevention. #HereditaryAngioedema #DrugDevelopment #Biopharma #Pharmaceuticals #ScientificResearch #PatientCare #RareDisease

I am excited to share that my scientific paper on direct oral challenges to cephalosporins (a class of β-lactam antibiotics) has been published in The Journal of Allergy and Clinical Immunology: In Practice. Over the past year, I coded and conducted statistical analysis of pediatric patients nationwide who have experienced an index reaction to a cephalosporin-based antibiotic, and subsequently underwent a direct graded oral challenge to confirm their suspected cephalosporin allergy. In 90% of cases, patients were deemed tolerant (negative challenge) to the antibiotic, which drastically helps reduce Canadian healthcare costs through a more accurate and cost-effective choice of antibiotic treatment. In cases of a positive challenge (10%), reactions consisted of mild, benign skin-limited rashes. Working closely with Dr. Ben-Shoshan of Montreal Children’s Hospital and other physicians across Canada, our work represents the first study to apply direct oral challenges to all children presenting with a suspected cephalosporin allergy. This project serves as a confirmation of direct oral challenges to cephalosporins as a safe and effective diagnostic tool for pediatric patients. Our work was also presented at The American Academy of Allergy, Asthma & Immunology Annual Conference in February 2023. I’d like to thank my co-authors for their contributions and support, and I look forward to promoting the importance of direct oral challenges to antibiotics as a diagnostic tool through my clinical work and future research. If you’d like to check out a snippet of my manuscript (or fully access through your institution), here’s the link: https://lnkd.in/e48cnVAW. Our work was selected by the JACI: In Practice editors as a “high-profile article of special clinical interest” to be highlighted in the Latest Research section of the American Academy of Allergy, Asthma & Immunology website, and a summary of its impact can be found here: https://lnkd.in/ekMh3Uup. In addition, the Montreal Children’s Hospital has provided a write-up on our findings, which you can read here: https://lnkd.in/eup--nT5.